Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Screening Europe

David Swinney's Biography

David Swinney, Chief Executive Officer, Institute for Rare and Neglected Diseases Drug Discovery

Dr. Swinney is co-founder of iRND3 and has over 20 years broad experience with Syntex and Roche as a leader in pre-clinical drug discovery, primarily in the inflammation and virology disease areas. His previous position was Director of Virology Biochemical Pharmacology at Roche Palo Alto. Dr. Swinney has devoted the majority of his career to the identification of tractable drug targets, effective mechanisms of drug action, and promising leads and clinical candidates to address unmet medical needs. He has also developed an expertise in the understanding and application of binding kinetics of drug discovery. Dr. Swinney has a PhD in medicinal chemistry from the University of Washington and is author of over 100 publications in the fields of biochemistry and pharmacology.

David Swinney Image

The Value of Phenotypic Screening to Drug Discovery

Tuesday, 17 February 2015 at 11:00

Add to Calendar ▼2015-02-17 11:00:002015-02-17 12:00:00Europe/LondonThe Value of Phenotypic Screening to Drug DiscoveryScreening Europe in Berlin, GermanyBerlin,

There is currently a renewed interest to effectively apply phenotypic screening to drug discovery.  In this talk I will address why phenotypic screening is of value to successful first-in-class drug discovery and how to realize this value.

Add to Calendar ▼2015-02-17 00:00:002015-02-18 00:00:00Europe/LondonScreening EuropeScreening Europe in Berlin, GermanyBerlin,